Purchase Summary

In order to access content on the FENIX Marketplace, you must have an account. You will also have access to FENIX Free updates.

The price for access is $599.00.

Account Information Already have an account? Log in here

Username

Password

Confirm Password

Work E-mail Address

Confirm E-mail Address

Occupation

Other

Full Name LEAVE THIS BLANK

Welcome Email

Send Welcome Email If selected, this user will receive an automated welcome email to the Marketplace Platform.

Send Welcome Email Again

I want to receive updates from fenix.group.

By selecting this, I agree to receive emails from fenix.group.

Processing...

You will be redirected to view the full article after purchasing. You will receive your account and payment information in a confirmation email, and can be viewed at any time in your Account.

RETURN TO HOME

$599

Dual/triple agonist, GLP-1RA, Other, Topics

November 04, 2026

Novo Raises FY 2026 Guidance as Wegovy Pill Revives Investor Sentiment; Q3 ’26 Earnings

Here is a brief preview of this blast: Novo hosted its Q3 ’26 earnings call and provided updates across its diabetes and obesity businesses (press release; slides). Following the call, Novo’s stock is up +7% after raising its FY 2026 adjusted sales guidance to +2% to +6% (from a prior range of 0% to +6%), reflecting an improved outlook across both business segments. Additionally, Wegovy pill delivered a strong quarter with sales of ~$831M exceeding consensus expectations, further contributing to a recovery in investor sentiment. Separately, Novo announced that CFO Karsten Munk Knudsen will step down at the end of 2026 and be succeeded by Luigi La Corte, who currently serves as CFO of Galderma (view LinkedIn post). Below, FENIX provides highlights and insights from the call.

About The Author

Matthew Maryniak

President of Fenix Group International

Matthew has been a thought leader in the high-growth therapeutic areas of diabetes and cardiovascular medicine since 2006, making regular attendance at large and small CV/met scientific meetings and an architect of novel methods for assessing market opportunities. He has over a decade of experience in leading CV/met consulting engagements, is a published author in PM360 and Diabetes Technology & Therapeutics, and has been quoted in The Pink Sheet on anti-thrombotics.